Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

• Main Authors: Ikaro Breder (Author), Jessica Cunha Breder (Author), Isabella Bonilha (Author), Daniel B. Munhoz (Author), Sheila T. Kimura Medorima (Author), Daniela C. Oliveira (Author), Helison R. do Carmo (Author), Camila Moreira (Author), Anatol Kontush (Author), Francesca Zimetti (Author), Ilaria Zanotti (Author), Luiz Sergio F. Carvalho (Author), Wilson Nadruz (Author), Elza Muscelli (Author), Thiago Quinaglia (Author), Andrei C. Sposito (Author)
• Format: Book
• Published: SAGE Publishing, 2020-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Patients with type 2 diabetes mellitus (T2DM) remain at increased cardiovascular residual risk and endothelial dysfunction, even after optimizing metabolic control and treatment by sodium-glucose-2 transporter inhibitors (SGLT2-is). The present study was based on the hypothesis that prop...